Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

Maria Teresa Voso, Massimo Breccia, Monia Lunghi, Antonella Poloni, Pasquale Niscola, Carlo Finelli, Alessia Bari, Pellegrino Musto, Renato Zambello, Luana Fianchi, Giuliana Alimena, Giuseppe Leone

Research output: Contribution to journalArticle

Abstract

In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important as prognosis postrelapse is poor. There is also the concern that early termination of treatment may result in rapid disease progression. We reviewed outcomes in 13 patients who discontinued azacitidine (decitabine in one patient) while still responding to the treatment. Most patients rapidly relapsed; median time to progression was 5.4 months. Reasons for treatment discontinuation included comorbidities, infections, and patient choice. These findings illustrate the risk of prematurely terminating azacitidine therapy in MDS.

Original languageEnglish
Pages (from-to)345-348
Number of pages4
JournalEuropean Journal of Haematology
Volume90
Issue number4
DOIs
Publication statusPublished - Apr 2013

Keywords

  • Azacitidine
  • Chronic myelomonocytic leukemia
  • Hypomethylating agents
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Voso, M. T., Breccia, M., Lunghi, M., Poloni, A., Niscola, P., Finelli, C., Bari, A., Musto, P., Zambello, R., Fianchi, L., Alimena, G., & Leone, G. (2013). Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. European Journal of Haematology, 90(4), 345-348. https://doi.org/10.1111/ejh.12079